Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Takeda’s Miyabashira Elected as New JPMA President
May 23, 2025
-
BUSINESS Japan Pharma Market Grows 1% to Record 11.4 Trillion Yen in FY2024: IQVIA
May 23, 2025
-
BUSINESS MSD Chief Decries Japan’s Unpredictable Policy Flip, Frets Future Investment
May 22, 2025
-
BUSINESS Sanofi Japan Seeing Improved Customer Satisfaction with AI-Powered Sales Support Tool
May 21, 2025
-
REGULATORY Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
-
ORGANIZATION PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
May 19, 2025
-
BUSINESS Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
-
REGULATORY Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval
May 15, 2025
-
REGULATORY Eylea’s Price to Be Axed by 19.5%, Jardiance 12.1% in Market Expansion Rule
May 15, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel Braced for Price Cuts after CEA
May 15, 2025
-
REGULATORY Chuikyo Plans Monthly Debates for CEA Reform in FY2026
May 15, 2025
-
REGULATORY Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA Scheme
May 15, 2025
-
REGULATORY Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
-
REGULATORY LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
-
ACADEMIA Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
-
BUSINESS J&J Taps Chris Rieger to Lead Japan Pharma Business
May 13, 2025
-
REGULATORY MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
-
BUSINESS Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
-
BUSINESS Lilly Japan Scores Double-Digit Growth for 2nd Year as Mounjaro Delivers
May 9, 2025
-
BUSINESS Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz
May 8, 2025
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…